1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
- Author
-
Bioque, M., Llerena, A., Cabrera, B., Mezquida, G., Lobo, A., González-Pinto, A., Díaz-Caneja, C.M., Corripio, I., Aguilar, E.J., Bulbena, A., Castro-Fornieles, J., Vieta, E., Lafuente, A., Mas, S., Parellada, M., Saiz-Ruiz, J., Cuesta, M.J., Bernardo, M., Gassó, P., Amoretti, S., García Bernardo, E., Tapia-Casellas, C., Alonso-Solís, A., Grasa, E., Hernández, M., González, I., Ruiz, P., Modrego, F., Escartí, M.J., Mané, A., Torrent, C., Baeza, I., Contreras, F., Albacete, A., Bobes, J., García-Portilla, Ma P., Zabala Rabadán, A., Segarra Echevarría, R., Rodriguez-Jimenez, R., Morales-Muñoz, I., Butjosa, A., Landin-Romero, R., Sarró, S., Ibáñez, Á., Sánchez-Torres, A.Ma, Balanzá-Martínez, V., and Universitat de Barcelona
- Subjects
Male ,Pediatrics ,medicine.medical_treatment ,Anticholinergic agents ,polytherapy ,Antipsychotic ,Pharmacovigilance ,0302 clinical medicine ,Pharmacology (medical) ,Antipsychotic drugs ,Child ,Clozapine ,Esquizofrènia -- Tractament ,First episode ,Drug monitoring ,Psychiatry and Mental health ,Treatment Outcome ,Schizophrenia ,Acute Disease ,Farmacovigilància ,schizophrenia ,Female ,Antipsychotic Agents ,Research Article ,medicine.drug ,Adult ,Seguretat dels pacients ,Farmacologia ,Psychosis ,medicine.medical_specialty ,Psychotropic drugs ,Adolescent ,medicine.drug_class ,Psicosi ,Atypical antipsychotic ,Psicofàrmacs ,Young Adult ,03 medical and health sciences ,Sex Factors ,first episode psychosis ,medicine ,Humans ,Espanya ,Psychiatry ,Patients safety ,Psychiatric Status Rating Scales ,Pharmacology ,business.industry ,Pharmacoepidemiology ,Psychoses ,medicine.disease ,psychotropic drugs ,030227 psychiatry ,Logistic Models ,Psychotic Disorders ,Spain ,Polypharmacy ,Antipsicòtics ,business ,030217 neurology & neurosurgery ,Farmacoepidemiologia - Abstract
BACKGROUND: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. METHODS: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. RESULTS: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P
- Published
- 2015
- Full Text
- View/download PDF